Trial tests Immune-Boosting drug duo against Tough-to-Treat cancer
NCT ID NCT03075527
Summary
This study tested a combination of two immunotherapy drugs, durvalumab and tremelimumab, for people with advanced pleural mesothelioma that had worsened after standard chemotherapy. The goal was to see if using these two drugs together could help the body's immune system fight the cancer more effectively. The trial was small and ended early, so its results are limited.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MESOTHELIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.